4Nathalie: Archive of a Family’s Campaign for Childhood Cancer

4Nathalie was a grassroots awareness campaign that began in 2012 around Nathalie Traller, a teenager from Oregon who was diagnosed with a rare cancer called alveolar soft part sarcoma (ASPS). This page is a neutral summary, written from archived material, of what the campaign described and why it drew public attention. It is not run by the family or by any organisation, and it does not solicit gifts of any kind.

The story as archived

According to the original site, Nathalie was diagnosed in April 2012 with stage IV ASPS, a rare sarcoma that does not respond well to standard chemotherapy. Her parents, who had earlier lived in Hawaii, researched clinical trials and treatment options and were in contact with specialists on both coasts of the United States. By autumn 2013 the disease was reported to be spreading, and sarcoma specialists pointed the family toward a new type of drug called anti-PD-1 immunotherapy.

The complication was her age. Trials of these drugs were enrolling adults only, so at 15 she could not join at least six studies she would otherwise have qualified for. Her oncologist therefore sought a route known as compassionate use, which lets a patient with a life-threatening illness receive an unapproved treatment outside a trial when a doctor and a drug maker agree.

The family and supporters ran a public campaign, with a hashtag, social media posts and media outreach, urging that teenagers be allowed into such trials. Local and national outlets covered it, as summarised on the media page. The archive states that after a campaign of about nine months she was offered access to treatment, and later pages from the site mention a trial opening to patients of her age. Subsequent pages refer to memorial tributes, which is why the project is treated here as an archive and not as a live appeal.

What the campaign tried to change

The material returns again and again to a few points about childhood cancer in general:

  • Cancers in young people are rare, so there is little commercial incentive to develop drugs for them.
  • Some paediatric cancers are still treated with chemotherapy regimens that date back decades.
  • Trial age cut-offs for new drugs can lock out teenagers even when there is no medical reason for it.
  • Wider public funding of childhood cancer research and incentives for paediatric drug development were requested from lawmakers.

The family’s own guidelines asked supporters to treat the scientists, regulators and companies involved with respect and described them as partners rather than opponents.

Read more